Platanias LC - Search Results

1

Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.

Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ. Platanias LC, et al. J Clin Oncol. 1991 Nov;9(11):2021-6. doi: 10.1200/JCO.1991.9.11.2021. J Clin Oncol. 1991. PMID: 1941061 Clinical Trial.

2

Treatment and prognosis of orbital non-Hodgkin's lymphomas.

Platanias LC, Putterman AM, Vijayakumar S, Recant W, Weichselbaum RR, Bitran JD. Platanias LC, et al. Am J Clin Oncol. 1992 Feb;15(1):79-83. doi: 10.1097/00000421-199202000-00015. Am J Clin Oncol. 1992. PMID: 1372464

3

Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.

Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ. Miller CB, et al. Among authors: platanias lc. J Natl Cancer Inst. 1992 Jan 15;84(2):98-103. doi: 10.1093/jnci/84.2.98. J Natl Cancer Inst. 1992. PMID: 1735886 Clinical Trial.

4

Hairy cell leukaemia: the role of alpha interferon.

Platanias LC, Ratain MJ. Platanias LC, et al. Eur J Cancer. 1991;27 Suppl 4:S53-7. doi: 10.1016/0277-5379(91)90575-x. Eur J Cancer. 1991. PMID: 1799481 Review.

5

Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.

Platanias LC, Ratain MJ, O'Brien S, Larson RA, Vardiman JW, Shaw JP, Williams SF, Baron JM, Parker K, Woodworth TG. Platanias LC, et al. Leuk Lymphoma. 1994 Jul;14(3-4):257-62. doi: 10.3109/10428199409049676. Leuk Lymphoma. 1994. PMID: 7950914 Clinical Trial.

6

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.

Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G. Nichols J, et al. Eur J Cancer. 1997 Jan;33 Suppl 1:S34-6. doi: 10.1016/s0959-8049(96)00327-9. Eur J Cancer. 1997. PMID: 9166099 Free article. Review.

7

Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.

LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC. LeMaistre CF, et al. Among authors: platanias lc. Blood. 1998 Jan 15;91(2):399-405. Blood. 1998. PMID: 9427692 Free article. Clinical Trial.

8

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.

Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC. Saleh MN, et al. Among authors: platanias lc. J Am Acad Dermatol. 1998 Jul;39(1):63-73. doi: 10.1016/s0190-9622(98)70403-7. J Am Acad Dermatol. 1998. PMID: 9674399 Clinical Trial.

9

Interleukin-1: biology, pathophysiology, and clinical prospects.

Platanias LC, Vogelzang NJ. Platanias LC, et al. Am J Med. 1990 Nov;89(5):621-9. doi: 10.1016/0002-9343(90)90181-c. Am J Med. 1990. PMID: 2239982 Review.

10

Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.

Goussetis DJ, Platanias LC. Goussetis DJ, et al. Among authors: platanias lc. Clin Cancer Res. 2010 Sep 1;16(17):4311-2. doi: 10.1158/1078-0432.CCR-10-1496. Epub 2010 Jul 9. Clin Cancer Res. 2010. PMID: 20622048 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

376 results

Search Page